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Abstract
The human REL proto-oncogene encodes a transcription factor in the NF-κB family. 
Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown 
to transform any mammalian lymphoid cell type. In this report, we show that overexpression of a 
highly transforming mutant of REL (RELΔTAD1) increases the oncogenic properties of the 
human B-cell lymphoma BJAB cell line, as demonstrated by increased colony formation in soft 
agar, tumor formation in SCID mice, and adhesion. BJAB-RELΔTAD1 cells also show decreased 
activation of caspase in response to doxorubicin. BJAB-RELΔTAD1 cells have increased levels of 
active nuclear REL protein as determined by immunofluorescence, subcellular fractionation, and 
electrophoretic mobility shift assay. Overexpression of RELΔTAD1 in BJAB cells has 
transformed the gene expression profile of BJAB cells from that of a germinal center B-cell 
subtype of diffuse large B-cell lymphoma (GCB-DLBCL) to that of an activated B-cell subtype 
(ABC-DLBCL), as evidenced by increased expression of many ABC-defining mRNAs. Up-
regulated genes in BJAB-RELΔTAD1 cells include several NF-κB targets that encode proteins 
previously implicated in B-cell development or oncogenesis, including BCL2, IRF4, CD40 and 
VCAM1. The cell system we describe here may be valuable for further characterizing the 
molecular details of REL-induced lymphoma in humans.
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Introduction
The human c-rel proto-oncogene (REL) encodes an NF-κB family transcription factor. 
Misregulated REL is associated with B-cell malignancies in several ways (Gilmore et al., 
2004). Overexpression of REL protein can transform chicken lymphoid cells in vitro. 
Additionally, the REL locus is amplified in several types of human B-cell lymphoma, 
including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and primary 
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mediastinal lymphoma. Moreover, REL mRNA is highly expressed in de novo DLBCLs, and 
this elevated expression correlates with increased expression of many putative REL target 
genes (Rhodes et al., 2005). Nevertheless, REL has not been shown to be oncogenic in any 
mammalian B-cell system, either in vitro or in vivo.
REL contains an N-terminal Rel Homology Domain, which mediates DNA binding, 
dimerization, nuclear localization, and binding to its inhibitor IκB. The C-terminal half of 
REL contains a transactivation domain, which can be divided into two subdomains (Martin 
et al., 2001; Starczynowski et al., 2003). Deletion of either C-terminal transactivation 
subdomain enhances the in vitro transforming activity of REL in chicken spleen cells 
(Starczynowski et al., 2003). Similarly, v-Rel lacks a transactivation subdomain found in 
avian c-Rel, and this deletion contributes to v-Rel’s increased transforming activity as 
compared to c-Rel (Gilmore, 1999). In addition, deletions and mutations that alter the REL 
transactivation domain have been identified in a small percentage of human B-cell 
lymphomas, and one such mutation can enhance the transforming activity of REL in chicken 
lymphoid cells (Kalaitzidis and Gilmore, 2002; Barth et al., 2003; Starczynowski et al., 
2007). Nevertheless, REL’s role in mediating oncogenesis in mammalian cells is not clear.
Herein, we show that overexpression of a REL mutant lacking transactivation subdomain 1 
(RELΔTAD1) enhances certain “transformed” properties of the human B-lymphoma cell 
line BJAB. Furthermore, RELΔTAD1-transformed BJAB cells have an altered gene 
expression profile that is consistent with them having been converted to a more aggressive 
form of DLBCL. As such, these results are the first direct demonstration that REL can 
contribute to human B-cell oncogenesis and describe an in vitro system for studying 
oncogenic conversion of B-cell lymphoma.
Results
Overexpression of RELΔTAD1 increases oncogenic properties of BJAB cells
A REL mutant (RELΔ424-490, or RELΔTAD1 herein) that is missing the first C-terminal 
transactivation subdomain has an enhanced ability to transform primary chicken spleen cells 
in vitro as compared to wild-type REL (Starczynowski et al., 2003). In an effort to establish 
a human cell assay for REL-induced oncogenesis, we first created an MSCV-based 
retroviral vector for expression of RELΔTAD1; as a control for our experiments, we used 
the MSCV vector backbone that contains only the puromycin resistance gene (Figure 1a).
Retroviral stocks of MSCV and MSCV-RELΔTAD1 were used to infect human B-
lymphoma BJAB cells, and these cells were then selected for puromycin resistance to 
establish stable pools of retrovirally transduced cells. By Western blotting, we identified a 
pool of MSCV-RELΔTAD1-transduced cells that expresses high levels of RELΔTAD1, 
which migrates faster than full-length endogenous REL (Figure 1b). The expression of 
RELΔTAD1 is approximately 2.4-fold greater than endogenous REL, which is expressed at 
approximately equal levels in both MSCV-RELΔTAD1-transduced cells and control 
MSCV-transduced cells. The expression of RELΔTAD1 was stable during more than six 
months of continued passage of MSCV-RELΔTAD1-transduced cells (not shown).
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To determine whether overexpression of RELΔTAD1 affects oncogenic properties of the 
BJAB cell line, we first compared the soft agar colony-forming abilities of MSCV-
RELΔTAD1 cells and MSCV-transduced cells. As shown in Figure 1c, BJAB-RELΔTAD1 
cells had an approximately 2.3-fold increased ability to form colonies in soft agar as 
compared to BJAB-MSCV cells. Moreover, colonies formed by BJAB-RELΔTAD1 cells 
were generally larger than those formed by BJAB-MSCV cells (not shown). Similarly, 
BJAB-RELΔTAD1 cells had increased tumor-forming ability in SCID mice (Table 1). 
Nevertheless, the growth rates of BJAB-MSCV and BJAB-RELΔTAD1 cells in liquid 
media were similar (Figure 1d). Doxorubin-induced activation of caspase-3 and cleavage of 
the caspase substrate PARP are delayed in BJAB-RELΔTAD1 cells as compared to BJAB-
MSCV cells; however, there is no difference in the ability of doxorubicin to decrease 
viability in these two cell types (Figure 1e).
RELΔTAD1-expressing BJAB cells have increased nuclear REL protein activity
As a first step towards determining the basis for the enhanced transformed properties of 
BJAB-RELΔTAD1 cells, we characterized RELΔTAD1 protein in these cells. By 
biochemical subcellular fractionation, BJAB-RELΔTAD1 cells showed increased nuclear 
REL protein—for both RELΔTAD1 and endogenous REL—as compared to BJAB-MSCV 
cells, in which the low level of endogenous REL is almost exclusively cytoplasmic (Figure 
2a). As controls for these fractionation experiments, we show that two cytoplasmic proteins 
(CD40 and 14-3-3) and a nuclear protein (RNA polymerase) are exclusively present in their 
respective fractions in both cell types. Indirect immunofluorescence showed that BJAB-
RELΔTAD1 cells have increased overall REL staining as compared to BJAB-MSCV cells 
and also have detectable nuclear REL staining (Figure 2b), which is not seen in BJAB-
MSCV cells. Nuclear extracts from BJAB-RELΔTAD1 cells also have increased levels of 
NF-κB p50, but not of RelA (Figure 2c).
BJAB-RELΔTAD1 cells show increased nuclear κB-site DNA-binding activity as compared 
to BJAB-MSCV cells (Figure 2d). The κB site-binding activity in BJAB-RELΔTAD1 cells 
was competed by the relevant unlabelled probe and was almost completely supershifted by 
anti-REL antiserum. Therefore, by three criteria, nuclear REL protein is increased in BJAB-
RELΔTAD1 cells as compared to control BJAB-MSCV cells.
In coimmunoprecipitations from BJAB cells, REL and RELΔTAD1 interact equally well 
with IκBα, suggesting that the changes in DNA binding and nuclear localization seen in 
BJAB-RELΔTAD1 cells are not due to changes in association with IκB (Supplementary 
Figure S1).
The expression of many known REL/NF-κB target genes is increased in RELΔTAD1-
expressing BJAB cells
We next compared the overall gene expression profiles of BJAB-RELΔTAD1 cells and 
BJAB-MSCV cells by using an extensive human microarray, which contains over 41,000 
probes, representing unique gene products. Using a two-fold change and P-value of less than 
0.005 (Holloway et al., 2008), we found that 538 mRNAs were decreased and 663 mRNAs 
were increased in BJAB-RELΔTAD1 cells (Supplementary Table S1). The levels of 67 
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transcripts were increased at least ten-fold in BJAB-RELΔTAD1 cells (Table 2). Serving as 
an internal control, REL mRNA showed approximately 25-fold increased expression in 
BJAB-RELΔTAD1 cells, presumably because the REL probe on the microarray can detect 
both endogenous REL and exogenous RELΔTAD1 mRNA/cDNA.
Several mRNAs that show greatly elevated expression in BJAB-RELΔTAD1 cells are 
known REL/NF-κB targets, including CXCR7 (77-fold increase), IRF4 (32-fold), CD44 (26-
fold), VCAM1 (24-fold), chemokine CCL22 (21-fold) and the anti-apoptotic protein BCL2 
(13.5-fold). However, out of approximately 400 reported REL/NF-κB targets (see www.nf-
kb.org), only approximately 4% were at least two-fold elevated in BJAB-RELΔTAD1 cells, 
94% were unchanged, and 2% were decreased by at least two-fold.
Based on cDNA profiling, DLBCLs have been divided into two main subtypes: GCB 
(germinal center B-cell type) and ABC (activated B-cell type) (Alizadeh et al., 2000; 
Rosenwald et al.,2002; Shipp et al., 2002; Wright et al., 2002; Ngo et al., 2006). This 
division is based on the observation that one subset of DLBCLs has a gene expression 
profile similar to B lymphocytes in the germinal center while another subset has a gene 
expression profile similar to activated peripheral B cells (Alizadeh et al., 2000). 
Furthermore, the ABC subtype has increased expression of several NF-κB target genes as 
compared to the GCB subtype, and survival of ABC cell lines depends on expression of 
these NF-κB target genes (Davis et al., 2001, Lam et al., 2008). BJAB cells have a gene 
expression profile that is consistent with the GCB subtype (Kalaitzidis et al., 2002; Ngo et 
al., 2006). Using the literature, we assembled a comprehensive set of genes that have been 
used to define these two subsets of DLBCL: 102 for ABC and 62 for GCB (see Tables S2 
and S3 for details). We then compared the levels of these ABC- and GCB-defining targets 
between BJAB-MSCV cells and BJAB-RELΔTAD1 cells, using a P-value < 0.005 as a cut-
off. Overall, 30% of the 102 ABC-profile genes were upregulated in the BJAB-RELΔTAD1 
cells (Table 3). We also found that BJAB cells overexpressing RELΔTAD1 showed 
increased expression of many of the ABC-defining genes that are NF-κB targets (Figure 3a): 
17/29 (59%) ABC-specific NF-κB target genes were upregulated in BJAB-RELΔTAD1 
cells (Table 3). Using the same filter criteria (P<0.005), only 6% of total transcripts showed 
increased expression in BJAB-RELΔTAD1 cells as compared to BJAB-MSCV cells.
We also found that 24% of the GCB-defining genes were downregulated in BJAB-
RELΔTAD1 cells as compared to BJAB-MSCV cells (Table 3). In contrast, only 9% of the 
total transcripts were downregulated in BJAB-RELΔTAD1 cells.
A statistical comparison of the percent change in ABC-subtype genes (30% upregulated, 
12% downregulated) versus GCB-subtype genes (10% upregulated, 24% downregulated) in 
BJAB-RELΔTAD1 cells (as compared to BJAB-MSCV cells) indicates that these two gene 
sets are affected in a significantly different manner (P-value, 0.0009; see Table 3).
To further analyze our gene expression data, we used Gene Ontology (http://
david.abcc.ncifcrf.gov/) to categorize genes upregulated in BJAB-RELΔTAD1 cells. We 
focused on upregulated genes because REL is primarily a transcriptional activator. Using 
this analysis, we were able to classify 563 of the 663 upregulated genes (>2-fold, P<0.005) 
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in BJAB-RELΔTAD1 cells; many of these upregulated genes encode proteins associated 
with cell surface processes/regions, including ones involved in cell-cell communication, the 
plasma membrane, the extracellular matrix, biological adhesion and signal transduction in 
general (Table 4).
In addition, we classified this same set of upregulated genes in BJAB-RELΔTAD1 cells by 
their biological function (www.ingenuity.com); by this analysis we were able to classify 421 
of 663 significantly upregulated genes. This analysis was consistent with our Gene Ontology 
annotation. Namely, over-represented molecular and cellular functions included those 
involved in cell-to-cell communication and cell growth and proliferation (Table 4). 
Furthermore, many genes (75 out of 421 annotated) that are statistically over-represented 
have been associated with immunological diseases (Table 4).
We next used RT-PCR to validate a subset of genes showing increased expression in BJAB-
RELΔTAD1 cells. As controls, we used a primer set that could amplify both endogenous 
REL and RELΔTAD1 to show that REL mRNA expression is increased in BJAB-
RELΔTAD1 cells as compared to BJAB-MSCV cells, whereas GAPDH expression is 
similar in both cell types (Figure 3b). Consistent with the microarray results, there was 
increased expression of BCL2, CCR7, IRF4 and VCAM1 mRNA in BJAB-RELΔTAD1 
cells. In contrast, CD10, a marker for GCB-type DLCBL (van Imhoff et al., 2006), showed 
reduced mRNA expression in BJAB-RELΔTAD1 cells. Western blotting showed that 
protein levels of BCL2, VCAM1, CD40 and REL are all elevated in BJAB-RELΔTAD1 
cells (Figure 3c), whereas CD10 protein is reduced in BJAB-RELΔTAD1 cells (Figure 3c). 
For CD40, the small (1.4-fold), but significant (P≤8.97 × 10−11), increase in CD40 mRNA 
in BJAB-RELΔTAD1 cells seen on the microarray was mirrored by an approximately 1.4-
fold increase in CD40 protein.
BJAB-RELΔTAD1 cells show increased adherence to culture dishes
During passage, we noticed that BJAB-RELΔTAD1 cells appeared to adhere more readily to 
culture plates than BJAB-MSCV cells. To compare the abilities of BJAB-MSCV and BJAB-
RELΔTAD1 cells to adhere, we plated both cell types on petri dishes, and cultured the cells 
for 36 h. We then visualized these cells before and after washing with PBS. As shown in 
Figure 4a, many BJAB-RELΔTAD1 cells remained attached to the culture dish after 
washing, whereas the BJAB-MSCV cells were removed by washing. We quantified this 
difference in adherence by comparing the numbers of floating versus adhering cells for each 
cell type: approximately five-fold more BJAB-RELΔTAD1 cells were attached to the dish 
as compared to the BJAB-MSCV cells (Figure 4b).
BJAB cells have low levels of endogenous REL protein expression
BJAB cells have previously been shown to have a low level of REL mRNA as compared to 
a number of other lymphoma cell lines (Leeman et al., 2008). To determine whether REL 
protein expression was also low in BJAB cells, we compared the expression of endogenous 
REL protein in BJAB cells to five other human B-cell lymphoma cell lines (SUDHL-4, RC-
K8, IB4, BL41 and Daudi). SUDHL-4 cells have been characterized as having a GCB 
profile, whereas RC-K8 cells have an ABC cDNA expression profile (Kalaitzidis et al., 
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2002). Among these six lymphoma cell lines, the expression of REL was lowest in BJAB 
cells (Figure 5a). As such, in BJAB cells, retrovirally transduced expression of RELΔTAD1 
is higher than endogenous REL, whereas in Daudi cells, RELΔTAD1 expression is lower 
than endogenous REL (Figure 5b). Moreover, expression of RELΔTAD1 did not enhance 
the soft agar colony ability of Daudi cells (Figure 5c), at least when expressed at the level in 
the cell line we analyzed here.
Discussion
This paper represents the first direct demonstration of an oncogenic effect of REL protein 
expression in a human B-lymphoid cell system. That is, we show that overexpression of an 
activated REL mutant, RELΔTAD1, increases the oncogenic properties of the human B-cell 
lymphoma BJAB cell line, as measured by increased soft agar colony-forming ability, tumor 
formation in immunocompromised mice, and adhesion. Moreover, the mRNA expression 
profile of BJAB cells overexpressing RELΔTAD1 is substantially altered; in particular, 
there is increased expression of many NF-κB target genes whose expression is associated 
with the more aggressive ABC subtype of diffuse large B-cell lymphoma. Furthermore, 
many of the up-regulated genes in BJAB-RELΔTAD1 cells can be classified as genes 
implicated in immunological diseases (Table 4), suggesting that BJAB-RELΔTAD1 cells 
have a phenotype that is more similar to aggressive DLBCL than is the GCB-like phenotype 
of control BJAB cells. As such, the cell system we describe here may provide an in vitro 
model system for understanding DLBCL transition from a low-grade (GCB-like) to a high-
grade (ABC-like) oncogenic state.
Although v-Rel, c-Rel and their derivatives have been shown to be oncogenic in avian and 
mouse systems (Gilmore, 1999; Gilmore et al., 2004), there has been controversy about 
whether REL is a true oncoprotein for human B-lymphoid cells (Shaffer et al., 2002; 
Houldsworth et al., 2004). For example, the REL gene is amplified in a high percentage of 
GCB-type DLBCLs, but these cells do not have particularly high levels of nuclear κB site-
binding activity (Davis et al., 2001). Moreover, the lack of oncogenic activity by 
overexpressed REL in mouse B-lymphoid cells in vitro or in vivo has cast doubt on whether 
REL acts as an oncoprotein in human B-cell malignancies, which are the sole human cancer 
cell type wherein the REL gene has been found to undergo amplification and mutation 
(Gilmore et al., 2004). The results we present herein strongly suggest that REL can exert an 
oncogenic effect in human B-lymphoma cells, and indicate that REL or certain REL target 
genes may be suitable therapeutic targets for some human B-cell lymphomas.
There are several likely explanations for the susceptibility of BJAB cells to the transforming 
activity of RELΔTAD1. First, BJAB cells express relatively low levels of endogenous REL 
protein (Figure 5a) as compared to several other human B-lymphoma cell lines. Thus, in 
BJAB cells it is possible to achieve a higher ratio of RELΔTAD1 protein to endogenous 
REL, and this relatively high level of RELΔTAD1 may be required for its transforming 
effect in human B cells. Second, BJAB cells have a GCB mRNA profile (Ngo et al., 2006), 
which is correlated with a better clinical outcome in DLBCL patients (Rosenwald et al., 
2002; Shipp et al., 2002), suggesting that BJAB cells are not as “transformed” as some other 
human B-cell lines. Third, in soft agar and tumor-forming assays similar to those we have 
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conducted here, BJAB cells have been shown to be susceptible to oncogenic effects of other 
factors, including the Epstein-Barr virus (EBV) LMP1 protein (Enberg et al., 1983; 
Wennborg et al., 1987), EBV small RNAs (Yamamoto et al., 2000) and the AP12-MALT1 
fusion protein from MALT lymphomas (Ho et al., 2005). Interestingly, LMP1 and AP12-
MALT1 are both inducers of NF-κB (Hammarskjold et al., 1992; Lucas et al., 2007) and 
both can increase the resistance of BJAB cells to inducers of apoptosis (Stoffel et al., 2004; 
Ho et al., 2005; Lucas et al., 2007). In addition, LMP1 can induce expression of BCL2 and 
IRF4, which are required for apoptosis resistance (Henderson et al., 1991; Finke et al., 1992; 
Snow et al., 2006), enhanced adhesion (Mainou and Raab-Traub, 2006), and cell motility 
(Mainou and Raab-Traub, 2006). Moreover, MALT1 chromosomal gains are also associated 
with ABC-subtype gene expression, including high levels of BCL2 expression and poorer 
prognosis (Dierlamm et al., 2008).
Many of the upregulated genes in BJAB-RELΔTAD1 cells are connected with processes 
that involve the plasma membrane, i.e., cell-to-cell communication, the extracellular matrix, 
adhesion, and membrane binding (see Table 4). These genes include VCAM1, CD44, CD40, 
ITGAX, and many chemokines and chemokine receptors including CCL22, CCR7, CXCR4 
and CXCL10. Additionally, BJAB-RELΔTAD1 cells are more adherent to a culture dish 
than control BJAB-MSCV cells (Figure 4). This is consistent with the large cohort of 
increased cDNAs in RELΔTAD1 cells that are classified as related to adhesion (Table 4). 
NF-κB signaling is also known to be downstream of many adhesion-related signaling 
pathways (Perez et al., 1994; Lee et al., 1999; Zarnegar et al., 2004). Furthermore, CD40 
and VCAM1 mRNA and protein expression are upregulated in the BJAB-RELΔTAD1 cells. 
While CD40 mRNA was only modestly increased (1.4-fold) in BJAB-RELΔTAD1 cells, 
this did translate into similarly increased CD40 protein levels (Figure 3c). CD40 has been 
shown to be important in B-cell aggregation (Lee et al., 1999), and both VCAM1 and CD40 
play roles in adhesion (Springer and Vonderheide, 1992; Lee et al., 1999). Taken together, 
these results suggest that overexpression of RELΔTAD1 in BJAB cells causes upregulation 
of many adhesion-associated genes, which results in a phenotype of the cells being more 
adherent, which may contribute to their enhanced ability to form colonies in soft agar and 
tumors in SCID mice.
BCL2 and IRF4, genes whose expression is up-regulated in BJAB-RELΔTAD1 cells, are 
markers for ABC DLBCL, whereas CD10 is down-regulated in both ABC DLBCLs and 
BJAB-RELΔTAD1 cells (Alizadeh et al., 2000; Wright et al., 2003). The increased 
expression of BCL2 in ABC DLBCLs correlates with a poorer clinical prognosis (Iqbal et 
al., 2006). The transcription factor IRF4 can synergize with v-Rel in the transformation of 
chicken fibroblasts and knockdown of IRF4 expression reduces the soft agar colony-forming 
ability of v-Rel-transformed cells (Hrdlicková et al., 2001). Of note, multiple myelomas are 
dependent on IRF4 for growth, whereas the growth of GCB-DLCBL does not require IRF4 
(Shaffer et al., 2008). Taken together, these results are consistent with BCL2 and IRF4 
playing a role in the enhanced transformed phenotype that we describe for BJAB-
RELΔTAD1 cells.
We also found that many other ABC-defining genes (including several not known to be NF-
κB targets) are significantly upregulated in BJAB-RELΔTAD1 cells. These ABC genes 
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include MARCKS, BATF, BMI1, LITAF and others (see Tables 2 and S2). Some of these 
ABC-type upregulated genes may reflect an overall shift in gene expression, induced 
indirectly by NF-κB/REL. In addition, some GCB-subtype genes are significantly down-
regulated in BJAB-RELΔTAD1 cells (Tables 3 and S3). These genes are, for the most part, 
non-NF-κB targets, suggesting that these decreases in GCB-type gene expression are also 
indirectly affected by RELΔTAD1.
Approximately 4% of total NF-κB targets (www.nf-kb.org) were up-regulated in BJAB-
RELΔTAD1 cells as compared to 59% of ABC-specific NF-κB targets (Table 2). The 
selective increase in expression of only a small number of NF-κB target genes in BJAB-
RELΔTAD1 cells suggests that the BJAB cells have been transformed to a more aggressive 
form of DLBCL by RELΔTAD1 through activation of a minor subset of NF-κB/REL 
targets. These ABC-specific NF-κB target genes may be poised for activation by 
RELΔTAD1 in B-lymphoma cells, possibly due to their chromosomal state or to cooperation 
of RELΔTAD1 with other B cell-specific transcription factors.
There are 40 genes whose expression is reduced by at least ten-fold in BJAB-RELΔTAD1 
cells (Table S1). The reduced expression of CD10 mRNA and protein in BJAB-RELΔTAD1 
cells (Figure 3) is consistent with the enhanced transformed properties of these cells, given 
that reduced CD10 expression correlates with a poorer prognosis in the clinic (van Imhoff et 
al., 2006). Gupta et al. (2008) have shown that expression of two B-cell proteins BLNK and 
BCAP are down-regulated directly by Rel in v-Rel-transformed avian cells. In our study, the 
level of only BLNK was significantly reduced in BJAB-RELΔTAD1 cells. Such results raise 
the possibility that down-regulation of gene expression is important for REL-induced effects 
on B-cell oncogenesis, and that some of these genes are specifically repressed by 
RELΔTAD1.
BJAB-RELΔTAD1 cells show a reduced induction of caspase-3 activity following treatment 
with 1 μg/ml doxorubicin, although the ability of doxorubicin to decrease viability is 
unchanged in BJAB-RELΔTAD1 cells (Figure 1e). These data are consistent with previous 
results showing that CD40 ligand, an inducer of NF-κB, can reduce the ability of this 
concentration of doxorubicin to induce caspase activity in BJAB cells without affecting its 
ability to induce apoptosis (Voorzanger-Rousselot et al., 1998). These results indicate that 
doxorubicin induces apoptosis in BJAB cells through a caspase-independent mechanism, 
which is not blocked by increased Rel/NF-κB activity.
The majority of the nuclear κB site-binding activity in RELΔTAD1-BJAB cells contains 
REL protein, whereas in control BJAB-MSCV cells, only a small fraction of the binding 
activity is supershifted by REL antiserum (Figure 2d). In addition, there are increased 
nuclear levels of NF-κB p50 in BJAB-RELΔTAD1 cells, presumably because RELΔTAD1 
and p50 readily interact (Figure S1). Taken together, these data suggest that a shift in the 
composition of nuclear NF-κB/REL dimers occurs upon overexpression of RELΔTAD1.
Only a small number of the genes upregulated by more than ten-fold in BJAB-RELΔTAD1 
cells are ABC-defining (5 genes) or known NF-κB targets (8 genes) (Table 2). As such, 
some of these genes may be novel ABC DLBCL markers or NF-κB/REL targets. In 
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addition, there are 14 ABC-defining genes that are significantly up-regulated in BJAB-
RELΔTAD1 cells that have yet to be classified as NF-κB/REL targets (Tables 3 and S2). 
Future work will be directed at determining which genes are direct RELΔTAD1 targets and 
which contribute to the phenotypic changes that occur in RELΔTAD1 “transformed” BJAB 
cells.
Material and methods
Plasmids, cell culture and infections
pMSCV has been described previously (Gilmore et al., 2003). pMSCV-RELΔTAD1 was 
created by subcloning a BglII to XhoI fragment containing the RELΔTAD1 cDNA into 
pMSCV.
Human A293T cells and BJAB or Daudi lymphoma cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 or 20% fetal bovine serum 
(Biologos, Montgomery, IL), respectively, as described (Starczynowski et al., 2005). Virus 
stocks were generated by transfecting A293T cells with pMSCV or pMSCV-RELΔTAD1 
plus helper plasmid pcL10a1, essentially as described previously (Gilmore et al., 2003). 
Approximately two days later, virus was harvested. One ml of virus (in the presence of 4 
μg/ml polybrene) was used to infect 106 BJAB or Daudi cells using the spin infection 
method (Gilmore et al., 2003). Two days later, cells were selected with 2.5 μg/ml puromycin 
(Sigma) for 2-4 weeks.
Soft agar colony assays and tumor formation assays
For soft agar assays, equal numbers of the indicated BJAB or Daudi cells (250, 500, 1000 or 
2000 cells) were placed in soft agar containing DMEM, 20% FBS and 0.3% bacto agar 
(Difco, Franklin Lakes, NJ), and plates were placed at 37°C in a humid incubator with 5% 
CO2. To confirm cell counts, total cell protein assays (Bio-Rad) were performed on the cell 
dilutions used for plating. Macroscopic soft agar colonies were counted 14 days after 
plating.
Tumor studies were performed essentially as described previously (Yamamoto et al., 2000; 
Gapuzan et al., 2002). 5 × 106 cells were injected subcutaneously into SCID mice (Taconic 
Farms, Germantown, NY). Once tumors appeared, mice were monitored 3× weekly and 
animals were sacrificed when tumors reached 2.25 mm2. All animal studies were performed 
in accordance with NIH guidelines and with approval of the Boston University Institutional 
Animal Care and Use Committee.
Caspase-3 and cell viability assays
Caspase-3 activity and cell viability following doxorubicin treatment were performed as 
described in Supplementary Material.
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Western blotting, indirect immunofluorescence, biochemical fractionation and 
electrophoretic mobility shift assays
Western blotting and indirect immunofluorescence were performed as described previously 
(Starczynowski et al., 2003, 2005). Details of antisera are in Supplementary Material. 
Indirect immunofluorescence was visualized using a confocal microscope (Olympus 
FLUOVIEW Laser Scanner Microscope BX 50, Center Valley, PA) (Starczynowski et al., 
2003).
Cytoplasmic and nuclear extracts were prepared as described previously (Liang et al., 2003), 
and were used either for Western blotting of equalized fractions or in electrophoretic 
mobility shift assays (nuclear extracts). EMSAs for κB-site binding were performed using 5 
μg of nuclear extracts as described previously (Kalaitzidis et al., 2002). For supershift 
assays, 1 μl of REL antiserum (#1507, gift of Nancy Rice) was added after protein/DNA 
complex formation, and samples were then incubated for an additional hour on ice 
(Kalaitzidis et al., 2002).
mRNA analysis: microarrays, data analysis and reverse transcriptase-PCR
The Agilent Whole Human Genome Microarray platform (product number G4112, Agilent 
Technology, Santa Clara, CA). This array contains 43,376 human oliognucleotide probes 
and also 1,468 positive controls and 153 negative controls. Within the array there are 
approximately 41,000 unique probes, which represent a smaller number of genes, reflecting 
the redundancy of the array platform. RNA was isolated from ~ 5 × 106 BJAB-MSCV and 
BJAB-RELΔTAD1 cells from four separate dishes for each on four separate days using 
Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA). RNA integrity was measured 
using an Agilent 2100 Bioanalyzer (Agilent Technology, Santa Clara, CA), and all samples 
had integrity values over 8.0. Samples from two RNA aliquots for each cell type were 
pooled, creating four pooled RNA samples: two of BJAB-MSCV and two of BJAB-
RELΔTAD1 cells. Sample labeling, hybridization to microarrays, scanning and calculation 
of normalized expression ratios were performed as previously described (Holloway et al., 
2008) at the Wayne State University Institute of Environmental Health Sciences microarray 
facility. As part of the platform, a dye swapping experiment was performed, where Alexa 
555-labeled cDNA from one of the BJAB-MSCV pools was mixed with Alexa 647-labeled 
cDNA from one of the BJAB-RELΔTAD1 pools. In a reciprocal dye swap, Alexa 647-
labeled cDNA from BJAB-MSCV cells was mixed with Alexa 555-labeled cDNA from 
BJAB-RELΔTAD1 cells.
The false discovery rate (FDR) was calculated as described previously (Clodfelter et al., 
2007). Briefly, a filter of P<0.005 was applied for statistical significance. Of the total probes 
on the array, 1592 met the two-fold expression difference cut-off criterion between the two 
cell types. The number of genes predicted to meet the combined threshold (P<0.005 and a 
greater than two-fold change in expression) by type I errors is 0.005 × 1592, or 8 genes. In 
our array, the actual number of genes having a two-fold expression change and a P<0.005 is 
1274. This corresponds to an FDR of 0.63% (8/1274). To eliminate duplicates in this 
analysis, we removed those genes with identical sequence names.
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RT-PCR was performed as described (Leeman et al., 2008). See Supplementary Material for 
details of primers and PCR conditions.
Adhesion assay
BJAB-MSCV and BJAB-RELΔTAD1 cells (1 × 106) were plated on petri dishes and were 
cultured for 36 h at 37°C and imaged. Cells were then washed once with PBS and the same 
field was imaged again using the same magnification (200 ×). To quantify the number of 
attached and floating cells, cells from triplicate dishes of each cell type were also isolated 
directly from the media and cells that remained adhered were collected separately. Both 
pools of cells were then lysed, and total protein was quantified from these lysates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We thank M Belmonte for help with tumor injections and microarray analysis, and M Garbati, J Leeman, D 
Kalaitzidis and D Starczynowski for helpful discussions. MC was supported by a Beckman Foundation 
Undergraduate Scholarship, MH was partially supported by a Pre-doctoral Fellowship from the Natural Sciences & 
Engineering Research Council of Canada, and NZ was partially supported by the Boston University Undergraduate 
Research Opportunities Program. This work was supported in part by the Superfund Basic Research Program at 
Boston University 5 P42 ES07381 (DJW) and NIH Grant CA047763 (TDG).
References
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse 
large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503–511. 
[PubMed: 10676951] 
Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, et al. Gains of 2p 
involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of 
classical Hodgkin lymphoma. Blood. 2003; 101:3681–3686. [PubMed: 12511414] 
Clodfelter KH, Miles GD, Wauthier V, Holloway MG, Zhang X, Hodor P, et al. Role of STAT5a in 
regulation of sex-specific gene expression in female but not male mouse liver revealed by 
microarray analysis. Physiol Genomics. 2007; 31:63–74. [PubMed: 17536022] 
Dierlamm J, Murga Penas EM, Bentink S, Wessendorf S, Berger H, Hummel M, et al. Gain of 
chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like 
gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-
cell lymphoma. Haematologica. 2008; 93:688–696. [PubMed: 18367485] 
Enberg I, Klein G, Biovanella BC, Stehlin J, McCormick KJ, Andersson-Anvret M, et al. Relationship 
between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two EBV-
negative lymphoma lines and their EBV-converted cell lines. Int J Cancer. 1983; 31:163–169. 
[PubMed: 6298125] 
Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NF-κB activity, function 
and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell 
lymphoma subtypes. Blood. 2005; 106:1392–1399. [PubMed: 15870177] 
Finke J, Fritzen R, Ternes P, Trivedi P, Bross KJ, Lange W, et al. Expression of bcl-2 in Burkitt’s 
lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood. 1992; 80:459–469. 
[PubMed: 1378321] 
Gapuzan M-E, Yufit PV, Gilmore TD. Immortalized embryonic mouse fibroblasts lacking the RelA 
subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene. 2002; 
21:2484–2492. [PubMed: 11971183] 
Chin et al. Page 11
Oncogene. Author manuscript; available in PMC 2009 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. 
Oncogene. 1999; 18:6925–6937. [PubMed: 10602467] 
Gilmore TD, Jean-Jacques J, Richards R, Cormier C, Kim J, Kalaitzidis D. Stable expression of the 
avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology. 2003; 316:9–16. 
[PubMed: 14599786] 
Gilmore TD, Kalaitzidis D, Liang M-C, Starczynowski DT. The c-Rel transcription factor and B-cell 
proliferation: a deal with the devil. Oncogene. 2004; 23:2275–2286. [PubMed: 14755244] 
Gupta N, Delrow N, Drawid A, Sengupta AM, Fan G, Gélinas C. Repression of B-cell linker (BLNK) 
and B-cell adaptor for phosphoinoside 3-kinase (BCAP) is important for lymphocyte 
transformation by Rel proteins. Cancer Res. 2008; 68:808–814. [PubMed: 18245482] 
Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the 
human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J 
Virol. 1992; 66:6496–6501. [PubMed: 1404600] 
Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 
expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from 
programmed cell death. Cell. 1991; 65:1107–1115. [PubMed: 1648447] 
Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, et al. MALT1 and the AP12-MALT1 
fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and 
resistance against FAS-induced cell death in B cells. Blood. 2005; 105:2891–2899. [PubMed: 
15598810] 
Holloway MG, Miles GD, Dombkowski AA, Waxman DJ. Liver-specific hepatocyte nuclear factor-4α 
deficieny: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol. 
2008; 22:1274–1286. [PubMed: 18276827] 
Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, et al. Relationship 
between REL amplification, REL function, and clinical and biologic features in diffuse large B cell 
lymphomas. Blood. 2004; 203:1862–1868. [PubMed: 14615382] 
Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. BCL2 expression is a 
prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin 
Oncol. 2006; 24:961–968. [PubMed: 16418494] 
Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell 
line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction 
pathway. Oncogene. 2002; 21:8759–8768. [PubMed: 12483529] 
Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-
oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002; 
34:129–135. [PubMed: 11921291] 
Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, et al. Compensatory IKKα activation of 
classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization 
screen. Proc Natl Acad Sci USA. 2008; 105:20798–20803. [PubMed: 19104039] 
Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. Specificities of CD40 signaling: 
involvement of TRAF2 in CD40-induced NF-κB activation and intracellular adhesion. Proc Natl 
Acad Sci USA. 1999; 96:1421–1426. [PubMed: 9990039] 
Leeman JR, Weniger MA, Barth TF, Gilmore TD. Deletion analysis and alternative splicing define a 
transactivation inhibitory domain in human oncoprotein REL. Oncogene. 2008; 27:6770–6781. 
[PubMed: 18695674] 
Liang M-C, Bardhan S, Li C, Pace EA, Porco JA Jr, Gilmore TD. Jesterone dimer, a synthetic 
derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear 
factor κB by inhibiting the inhibitor of κB kinase. Mol Pharmacol. 2003; 64:123–131. [PubMed: 
12815168] 
Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol. 2006; 
80:6458–6468. [PubMed: 16775333] 
Martin AG, San-Antonio B, Fresno M. Regulation of nuclear factor κB transactivation: implications of 
phosphatidylinositol 3-kinase and protein kinase Cζ in c-Rel activation by tumor necrosis factor α. 
J Biol Chem. 2001; 276:15840–15849. [PubMed: 11278885] 
Chin et al. Page 12
Oncogene. Author manuscript; available in PMC 2009 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference 
screen for molecular targets in cancer. Nature. 2006; 441:106–110. [PubMed: 16572121] 
Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix cata. Bioinformatics. 2003; 19:295–
296. [PubMed: 12538257] 
Perez JR, Higgins-Sochaski KA, Maltese JY, Narayanan R. Regulation of adhesion and growth of 
fibrosarcoma cells by NF-κB RelA involves transforming growth factor beta. Mol Cell Biol. 1994; 
14:5326–5332. [PubMed: 8035811] 
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for 
regulatory programs in the cancer transcriptome. Nat Genet. 2005; 37:579–583. [PubMed: 
15920519] 
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular 
profiling to predict survival after chemotherapy for diffuse large B-ell lymphoma. N Engl J Med. 
2002; 346:1937–1947. [PubMed: 12075054] 
Shaffer AL, Rosenwald A, Staudt LM. Decision making in the immune system: Lymphoid 
malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002; 2:920–933. 
[PubMed: 12461565] 
Shaffer AL, Tolga Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple 
myeloma. Nature. 2008; 454:226–231. [PubMed: 18568025] 
Shipp MA, Ross KN, Tamayo P, Weng AP, Lutok JL, Aguiar RCT, et al. Diffuse large B-cell 
lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat 
Med. 2002; 8:68–74. [PubMed: 11786909] 
Snow AL, Lambert SL, Natkunam Y, Esquival CO, Krams SM, Martinez OM. EBV can protect 
latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006; 
177:3283–3293. [PubMed: 16920969] 
Springer TA, Vonderheide RH. Lymphocyte adhesion through very late antigen 4: evidence for a 
novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an 
additional alpha 4 integrin counter-receptor on stimulated endothelium. J Exp Med. 1992; 
175:1433–1442. [PubMed: 1375259] 
Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation 
subdomain enhances the in vitro transforming activity of human transcription factor REL in 
chicken spleen cells. Oncogene. 2003; 22:6928–6936. [PubMed: 14534540] 
Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor α-responsive serine 
residues within the C-terminal transactivation domain of human transcription factor REL enhance 
its in vitro transforming ability. Oncogene. 2005; 24:7355–7368. [PubMed: 16027730] 
Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, et al. Mutation of an IKK 
phosphorylation site within the transactivation domain of REL in two patients with B-cell 
lymphoma enhances REL’s in vitro transforming activity. Oncogene. 2007; 26:2685–1694. 
[PubMed: 17072339] 
Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-κB and inhibition of p53-mediated 
apoptosis by AP12/Mucosa-Associated Lymphoid Tissue 1 fusions promote oncogenesis. Proc 
Natl Acad Sci USA. 2004; 101:9079–9084. [PubMed: 15184680] 
van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, et al. 
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-
risk diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24:4135–4142. [PubMed: 16943530] 
Voorzanger-Rousselot N, Favrot M-C, Blay J-Y. Resistance to cytotoxic chemotherapy induced by 
CD40 ligand in lymphoma cells. Blood. 1998; 92:3381–3387. [PubMed: 9787177] 
Wennborg A, Aman P, Saranath D, Pear W, Sümegi J, Klein G. Conversion of the lymphoma cell line 
“BJAB” by Epstein-Barr virus into phenotypically altered sublines is accompanied by increased c-
myc RNA levels. Int J Cancer. 1987; 40:202–206. [PubMed: 3038758] 
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to 
diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 
2003; 100:9991–9996. [PubMed: 12900505] 
Chin et al. Page 13
Oncogene. Author manuscript; available in PMC 2009 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yamamoto N, Takizawa T, Iwanaga Y, Shimizu N, Yamamoto N. Malignant transformation of B 
lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett. 2000; 484:153–
158. [PubMed: 11068051] 
Zarnegar B, He JQ, Oganesyan G, Hoffman A, Baltimore D, Cheng G. Unique CD40-mediated 
biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. 
Proc Natl Acad Sci USA. 2004; 101:8108–8113. [PubMed: 15148378] 
Chin et al. Page 14
Oncogene. Author manuscript; available in PMC 2009 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Overexpression of RELΔTAD1 increases the soft agar colony-forming ability of BJAB 
cells. (a) Structure of MSCV retroviral vectors used in these studies. (b) Anti-REL Western 
blotting of cells stably transduced with MSCV or MSCV-RELΔTAD1 (RELΔTAD1). 
Endogenous REL and introduced RELΔTAD1 are indicated. (c) Relative soft agar colony 
formation of BJAB-MSCV cells (1.0) and BJAB-RELΔTAD1 cells. Values are the averages 
of four assays performed in triplicate; error bars indicate standard error. (d) Comparison of 
the proliferation of BJAB-MSCV cells and BJAB-RELΔTAD1 cells. Cells were plated at 
105 cells/well and were counted each day following plating. (e) BJAB-MSCV cells (MSCV) 
and BJAB-RELΔTAD1 cells (ΔTAD1) were treated with 1 μg/ml doxorubicin (DOX) for 
the indicated times and caspase-3 activity was measured or PARP cleavage was monitored 
by Western blotting (bottom panel). For each cell type, caspase activity is relative to the 
activity seen with untreated cells at the same time point (1.0). Cell viability was measured 
after treatment with 1.0 μg/ml of doxorubicin at the indicated time points (right panel). 
Values are the averages of four (caspase-3 activity) or three experiments (cell viability), 
each performed with triplicate samples.
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Figure 2. 
BJAB-RELΔTAD1 cells have increased nuclear REL protein activity as compared to BJAB-
MSCV cells. BJAB-RELΔTAD1 cells and BJAB-MSCV cells were compared by 
subcellular fractionation (a, c), indirect immunofluorescence using an anti-REL primary 
antiserum (b), and by EMSA analysis of nuclear extracts (d). In (a) and (c), nuclear (N) and 
cytoplasmic fractions (C) were subjected to Western blotting using equal proportions of 
each fraction for analysis of REL, p50, RelA, and 14-3-3 and CD40 proteins (as cytoplasmic 
controls) or RNA polymerase II (as a nuclear control). In (b), the indicated BJAB cells were 
stained with an anti-REL antibody and viewed by confocal microscopy. The left panel 
contains BJAB-RELΔTAD1 cells; the middle and right panels show BJAB-MSCV cells. 
The left and middle panels were imaged using the same exposure time (Exp), while the right 
panel was imaged using a longer exposure time to detect the low level of endogenous REL 
in BJAB-MSCV cells. In (d), an EMSA was performed on equalized amounts (5 μg) of 
nuclear extracts using a κB-site probe from the human MHC1 enhancer. Where indicated, 
competitions were performed using an excess of cold probe or samples were supershifted 
(SS) using anti-REL antiserum. The relevant complexes are indicated.
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Figure 3. 
Analysis of mRNA and protein from select genes in BJAB-MSCV and BJAB-RELΔTAD1 
cells. (a) Heat map of NF-κB-specific ABC-target gene expression in BJAB-RELΔTAD1 
cells as compared to BJAB-MSCV cells. The map was created using the matrix2png 
program (Pavlidis and Noble, 2003). The expression scale is shown below the map. (b) RT-
PCR of the indicated mRNAs: BCL2, IRF4, CCR7, CD10, VCAM1, REL (as a positive 
control), and GAPDH (as a normalization control). Water control (-); BJAB-MSCV 
(MSCV); BJAB-RELΔTAD1 (RELΔTAD1). (c) Western blotting for REL, VCAM1, BCL2, 
CD40, CD10 and β-actin (as a normalization control) of extracts from BJAB-MSCV cells 
(MSCV) and BJAB-RELΔTAD1 cells (RELΔTAD1).
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Figure 4. 
BJAB-RELΔTAD1 cells show increased adherence to culture dishes. (a) BJAB-MSCV and 
BJAB-RELΔTAD1 cells (1×106) were grown in petri dishes for 36 h and imaged at 200 × 
magnification (top panel); dishes were then washed with PBS and cells in the same field 
were imaged again (“Washed” panels). The arrows point to a clump of BJAB-RELΔTAD1 
cells that adhere to the culture dish. (b) The percentage of attached cells was determined by 
measuring the total protein content of floating cells isolated directly from the media and 
from cells that remained attached to the culture dish. The assay was performed with 
triplicate plates; error bars represent standard error.
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Figure 5. 
Expression of REL in several human B-lymphoma cell lines. (a) The following human B-
lymphoma cell lines were used: BJAB (EBV-negative Burkitt-like lymphoma), SUDHL-4 
(DLBCL), RC-K8 (DLBCL), IB4 (umbilical cordblood B-cell lymphoblastoid line infected 
with EBV), Daudi (EBV-positive Burkitt’s lymphoma), and BL41 (Burkitt’s lymphoma). 
Lysates were prepared from actively growing cells, and 20 μg of total protein was analyzed 
by anti-REL Western blotting (top). At the bottom is shown a Coomassie blue-stained gel of 
equalized total protein extracts. Rel. Amt. indicates the relative amount of REL in each cell 
type, as compared to BJAB cells (1.0), determined by scanning of the film in the top panel. 
(b) Anti-REL Western blotting of control BJAB cells, BJAB-RELΔTAD1 cells, control 
Daudi cells, and a Daudi-RELΔTAD1 cell line. (c) Relative soft agar colony forming ability 
of control vs Daudi-RELΔTAD1 cells. Assays were performed as in Figure 1c, values are 
the averages of 5 experiments performed with triplicate plates, and were normalized to the 
number of colonies obtained with control Daudi cells (1.0).
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Table 1
Tumor-forming abilities of BJAB-RELΔTAD1 and BJAB-MSCV cells in SCID mice
Cell type Number of mice injecteda Number of tumorsb % Tumors formedc
BJAB-MSCV 7 6 43%
BJAB-RELΔTAD1 7 11 79%
Using a chi-square test, a P-value = 0.05 was obtained for the difference in tumor number between control BJAB-MSCV and BJAB-RELΔTAD1 
cells.
a
Mice were injected above both right and left hind limbs (two injections/mouse) with 5 × 106 cells/site.
b
Tumors were monitored for up to 7 weeks post-injection.
c
Percentage of tumor formation (tumors/14 injection sites × 100).
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Table 3
ABC and GCB genes whose expression is altered in RELΔTAD-BJAB cells
Gene type Total number
of genes No.upregulated
No.
downregulated
No.
unchanged
All ABC-specific genes 102 31 (30%) 12 (12%) 59 (58%)
ABC-NF-κB targets 29 17 (59%) 2 (7%) 10 (34%)
All GCB-specific genes 62 6 (10%) 15 (24%) 41 (66%)
GCB-NF-κB targets 3 2 (67%) 1 (33%) 0 (0%)
Gene lists were obtained using previously classified ABC and GCB-specific genes (Alizadeh et al., 2000; Rosenwald et al., 2002; Wright et al., 
2002; Feuerkhake et al., 2005; Ngo et al., 2006) and NF-κB targets were obtained from www.nf-kb.org. See Tables S2 and S3 for complete gene 
lists, references and annotations. Listed are the numbers of genes that are upregulated, downregulated or unchanged in RELΔTAD1 cells compared 
to BJAB-MSCV cells within a given subset. The genes with altered expression were classified based on a P-value cut-off of 0.005. Genes were 
grouped into ABC-specific genes, ABC-specific NF-κB targets, GCB-specific genes and GCB-specific NF-κB target genes. To validate the 
patterns of ABC and GCB gene expression distribution in BJAB-RELΔTAD1 cells, we calculated the P-value of the two gene sets (ABC, 31 and 
12 versus GCB, 6 and 15) using a two-tailed chi-square test at 95% confidence using Graphpad Prism 4 software (Graphpad Prism Software, San 
Diego, CA). These two gene sets differed with a highly significant P-value (0.0009). That is, the percentage of upregulated ABC-genes and the 
percentage of downregulated GCB-genes in BJAB-RELΔTAD1 cells are significantly different from one another.
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Table 4
Gene Ontology classifications for upregulated genes in the BJAB-RELΔTAD1 cells
Gene ontology No. of genes P-value
Protein function
Intrinsic to plasma membrane 73 2.80 × 10−10
Extracellular region part 52 9.70 × 10−9
Cell communication 157 3.10 × 10−8
Signal transduction 144 1.30 × 10−7
Biological adhesion 45 7.60 × 10−7
Immune response 50 2.00 × 10−6
Membrane part 205 5.50 × 10−6
Protein binding 227 3.60 × 10−6
Biological function
Diseases and disorders
   Immunological disease 75 1.12 × 10−10− 1.99 × 10−3
   Connective tissue disorder 52 5.07 × 10−9− 1.50 × 10−3
Molecular and cellular functions
   Cellular growth and proliferation 144 4.88 × 10−10− 1.88 × 10−3
   Cell to cell signaling and interaction 114 1.73 × 10−9− 1.50 × 10−3
Physiological system development and function
   Immune and lymphatic system development and function 84 2.01 × 10−10− 1.98 × 10−3
   Tissue morphology 71 2.01 × 10−10− 1.88 × 10−3
Gene Ontology grouping of the functions of the upregulated genes (563 annotated total) in RELDTAD1 cells. Shown at the top are the protein 
functions of the GO-terminology groupings with the lowest P-values (http://david.abcc.ncifcrf.gov/). In the bottom half of the table are the 
biological groupings of 421 significantly upregulated genes that were annotated in the Ingenuity Pathways Analysis program 
(www.ingenuity.com). Shown are the classifications based on the lowest P-values. Ranges of P-values refer to the fact that multiple subcategories 
are included in these classifications.
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